FDA has approved Dovato, the first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment
The FDA ( U.S. Food and Drug Administration ) has approved Dovato ( Dolutegravir and Lamivudine ), as a complete regimen for the treatment of human immunodeficiency virus type 1 ( HIV-1 ) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato.
This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.
Currently, the standard of care for patients who have never been treated is a three-drug regimen. With this approval, patients who have never been treated have the option of taking a two-drug regimen in a single tablet while eliminating additional toxicity and potential drug interactions from a third drug.
Approximately 1.1 million people in the U.S. are living with HIV. About 15% of them ( 1 in 7 ) are unaware they are infected.
Effective treatment is important in reducing the amount of virus in the blood. A suppressed viral load in people living with HIV prevents disease progression, and helps them live longer, healthier lives.
Also, people living with HIV who take HIV medication daily as prescribed and maintain an undetectable viral load have effectively no risk of sexually transmitting HIV to their HIV-negative partners.
The Dovato labeling includes a Boxed Warning, which cautions that patients infected with both HIV and hepatitis B should add additional treatment for their hepatitis B or consider a different drug regimen.
Patients with both HIV and hepatitis B who take products containing Lamivudine, an ingredient in Dovato, have developed hepatitis B variants associated with resistance to Lamivudine and may have severe liver problems, including liver failure, when they stop taking drugs containing Lamivudine.
Patients who have both HIV and hepatitis B virus who stop using Dovato should be closely monitored by their health care provider.
The efficacy and safety of Dovato, one tablet taken daily, were demonstrated in two identical, randomized, double-blind, controlled clinical trials in 1,433 HIV-infected adults with no prior antiretroviral treatment history.
The trials showed that a drug regimen containing Dolutegravir and Lamivudine had a similar effect of reducing the amount of HIV in the blood compared to another drug regimen, which included Dolutegravir, Emtricitabine, and Tenofovir.
The treatment was considered successful if the patient maintained low-levels ( less than 50 copies/mL ) of HIV RNA in their blood for at least 48 weeks.
The most common adverse reactions with Dovato were headache, diarrhea, nausea, insomnia and fatigue.
As there is a known risk for neural tube defects with Dolutegravir, patients are advised to avoid use of Dovato at the time of conception through the first trimester of pregnancy.
In May 2018, the FDA released a Drug Safety Communication regarding reported neural tube birth defects in babies born to women treated with Dolutegravir. ( Xagena )
Source: FDA, 2019
Keytruda plus Lenvima combination for patients with certain types of advanced endometrial carcinoma - FDA approved
The U.S. Food and Drug Administration ( FDA ) has approved the combination of Keytruda ( Pembrolizumab ), an anti-PD-1...
Tecentriq in combination with Avastin for the treatment of people with unresectable hepatocellular carcinoma, European Commission approved
The European Commission has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ) for the treatment of...
The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA...
Keytruda for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as monotherapy...
The use of convalescent plasma is not new; it was used for severe acute respiratory syndrome ( SARS ), pandemic...
FDA: Opdivo plus Yervoy as first-line treatment of patients with metastatic non-small cell lung cancer with PD-L1 expression greater than or equal to 1%
Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was...
FDA has approved Tecentriq in combination with Avastin for people with unresectable or metastatic hepatocellular carcinoma
The FDA ( U.S. Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with Avastin (...
Patients with chronic viral hepatitis: lipophilic statins were associated with significantly reduced hepatocellular carcinoma incidence and mortality
Whether statin type influences hepatocellular carcinoma ( HCC ) incidence or mortality in chronic hepatitis B or C virus infection...
Direct-acting antivirals reduce risk of premature mortality and liver cancer for patients with chronic hepatitis C
The first prospective, longitudinal study investigating treatment of chronic hepatitis C with direct-acting antivirals finds that the treatment is associated...
Adults and children with all genotypes of hepatitis C and compensated cirrhosis: Mavyret shortens duration of treatment to eight weeks, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...